Acadia Pharmaceuticals Inc (NASDAQ:ACAD) has 325 institutional investors that have filed 13F reports for the period ending December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| BlackRock, Inc. | 31 Dec, 2025 | 0 | 486,808 | 2.40% | $0.00 |
| BAKER BROS. ADVISORS LP | 31 Dec, 2025 | 0 | 0 | 0.00% | $0.00 |
| Point72 Asset Management, L.P. | 31 Dec, 2025 | 0 | 1,890,954 | 127.22% | $0.00 |
| Rockefeller Capital Management L.P. | 31 Dec, 2025 | 0 | 1,189,767 | 114.81% | $0.00 |
| VANGUARD GROUP INC | 31 Dec, 2025 | 0 | -25,414 | -0.17% | $0.00 |
| BRAIDWELL LP | 31 Dec, 2025 | 0 | -346,634 | -14.57% | $0.00 |
| Barclays Plc | 31 Dec, 2025 | 0 | -344,247 | -48.31% | $0.00 |
| State Street Corp | 31 Dec, 2025 | 0 | 655,257 | 9.03% | $0.00 |
| Pictet Asset Management Holding SA | 31 Dec, 2025 | 0 | 84,055 | 5.75% | $0.00 |
| HSBC HOLDINGS PLC | 31 Dec, 2025 | 0 | 21,781 | 70.74% | $0.00 |
| RTW INVESTMENTS, LP | 31 Dec, 2025 | 0 | 0 | 0.00% | $0.00 |
| Trails Edge Capital Partners, LP | 31 Dec, 2025 | 0 | 1,419,406 | 0.00% | $0.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 31 Dec, 2025 | 0 | 106,807 | 3.41% | $0.00 |
| Frazier Life Sciences Management, L.P. | 31 Dec, 2025 | 0 | 683,361 | 111.33% | $0.00 |
| DIMENSIONAL FUND ADVISORS LP | 31 Dec, 2025 | 0 | 122,840 | 4.39% | $0.00 |
| Qube Research & Technologies Ltd | 31 Dec, 2025 | 0 | 606,159 | 101.63% | $0.00 |
| Palo Alto Investors LP | 31 Dec, 2025 | 0 | 17,347 | 0.70% | $0.00 |
| FIRST TRUST ADVISORS LP | 31 Dec, 2025 | 0 | 326,882 | 16.82% | $0.00 |
| Nuveen, LLC | 31 Dec, 2025 | 0 | 103,533 | 10.85% | $0.00 |
| Goldman Sachs Group Inc | 31 Dec, 2025 | 0 | -532,399 | -25.32% | $0.00 |